AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37053429 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Number of subjects: 49
Study 37053529 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Insulin Delivery
Number of subjects: 0
Study 37053529 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard insulin delivery)
Number of subjects: 0
Study 37053531 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary hemoglobin A1c (HbA1c) collection
Number of subjects: 258
Study 37053531 — intervention group
Group type: COMPARATOR
Intervention: Venous hemoglobin A1c (HbA1c) measurement
Number of subjects: 258
Study 37053535 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib (MEK1/2 inhibitor)
Number of subjects: 50
Study 37054503 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine receptor kinase inhibitor (TRKi) treatment in patients with simple genomics NMT.
Number of subjects: 188
Study 37054503 — intervention group
Group type: COMPARATOR
Intervention: First-generation TRKi treatment in patients with complex genomics NMT.
Number of subjects: 188
Study 37054503 — intervention group
Group type: COMPARATOR
Intervention: Median metastatic survival in patients with complex genomics NMT.
Number of subjects: 188
Study 37054556 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus platinum chemotherapy (GC) + bevacizumab
Number of subjects: 34
Study 37054556 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus platinum chemotherapy (GC)
Number of subjects: 34
Study 37054556 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 34
Study 37054807 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive online childbirth education platform (Birthly) combined with usual prenatal education
Number of subjects: 90
Study 37054807 — intervention group
Group type: COMPARATOR
Intervention: Usual prenatal education alone
Number of subjects: 90
Study 37054888 — intervention group
Group type: EXPERIMENTAL
Intervention: β-glucan 1.5 g
Number of subjects: 263
Study 37054888 — intervention group
Group type: EXPERIMENTAL
Intervention: β-glucan 3 g
Number of subjects: 263
Study 37054888 — intervention group
Group type: EXPERIMENTAL
Intervention: β-glucan 6 g
Number of subjects: 263
Study 37054888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study 37054888 — intervention group
Group type: EXPERIMENTAL
Intervention: All β-glucan groups
Number of subjects: 263
Study 37054888 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 263
Study 37054897 — intervention group
Group type: EXPERIMENTAL
Intervention: Online mindfulness-based intervention (MBI)
Number of subjects: 219
Study 37054897 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 219
Study 37054898 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Modification Programme plus Information and Communication Technologies (LMP + ICTs)
Number of subjects: 188
Study 37054908 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angiography-derived IMR (caIMR)
Number of subjects: 113
Study 37055189 — intervention group
Group type: EXPERIMENTAL
Intervention: PENG block
Number of subjects: 60
Study 37055189 — intervention group
Group type: COMPARATOR
Intervention: Sham block
Number of subjects: 60
Study 37055198 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 L NC 100% oxygen
Number of subjects: 120
Study 37055198 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (no respiratory support)
Number of subjects: 120
Study 37055201 — intervention group
Group type: EXPERIMENTAL
Intervention: UC plus access to Stand Down (App)
Number of subjects: 274
Study 37055201 — intervention group
Group type: EXPERIMENTAL
Intervention: UC plus Peer-Supported Stand Down (PSSD) - four peer-led phone sessions over the initial 8 weeks
Number of subjects: 274
Study 37055201 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 274
Study 37055203 — intervention group
Group type: EXPERIMENTAL
Intervention: Goat milk formula (whey:casein ratio of 20:80, 50% milk fat from whole goat milk)
Number of subjects: 2296
Study 37055203 — intervention group
Group type: COMPARATOR
Intervention: Cow milk formula (control, whey:casein ratio of 60:40, 100% lipids from vegetable oils)
Number of subjects: 2296
Study 37055203 — intervention group
Group type: EXPERIMENTAL
Intervention: Goat milk formula
Number of subjects: 2296
Study 37055203 — intervention group
Group type: COMPARATOR
Intervention: Cow milk formula
Number of subjects: 2296
Study 37055205 — intervention group
Group type: EXPERIMENTAL
Intervention: SIESTA in combination with treatment as usual (TAU) for ADHD
Number of subjects: 0
Study 37055205 — intervention group
Group type: COMPARATOR
Intervention: TAU only
Number of subjects: 0
Study 37055205 — intervention group
Group type: EXPERIMENTAL
Intervention: SIESTA
Number of subjects: 0
Study 37055207 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC+L (Leflunomide 100 mg/day for 3 days followed by 10-20 mg/day for 7 days)
Number of subjects: 214
Study 37055207 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC+L
Number of subjects: 214
Study 37055207 — intervention group
Group type: COMPARATOR
Intervention: SOC
Number of subjects: 214
Study 37055213 — intervention group
Group type: EXPERIMENTAL
Intervention: Femom (NIFECG)
Number of subjects: 0
Study 37055213 — intervention group
Group type: COMPARATOR
Intervention: cCTG monitoring
Number of subjects: 0
Study 37055214 — intervention group
Group type: EXPERIMENTAL
Intervention: HABIT-ILE (50 hours over 2 weeks)
Number of subjects: 48
Study 37055214 — intervention group
Group type: COMPARATOR
Intervention: Usual motor activity and regular rehabilitation
Number of subjects: 48
Study 37055215 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (TH)
Number of subjects: 0
Study 37055215 — intervention group
Group type: COMPARATOR
Intervention: Matched peers without NE
Number of subjects: 0
Study 37055276 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pectoralis II and serratus anterior plane blocks (ultrasound-guided, using a mixture of plain and liposomal bupivacaine)
Number of subjects: 194
Study 37055276 — intervention group
Group type: COMPARATOR
Intervention: Routine analgesia
Number of subjects: 194
Study 37055276 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pectoralis II and serratus anterior plane blocks
Number of subjects: 194
Study 37055279 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with 6 cycles of gemcitabine
Number of subjects: 125
Study 37055279 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy with 3 cycles of gemcitabine followed by chemoradiation therapy (CRT) and another 3 cycles of gemcitabine
Number of subjects: 125
Study 37055279 — intervention group
Group type: EXPERIMENTAL
Intervention: CA19-9 response to initial adjuvant gemcitabine
Number of subjects: 125
Study 37055279 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative CA19-9 levels
Number of subjects: 125
Study 37055279 — intervention group
Group type: EXPERIMENTAL
Intervention: CA19-9 response
Number of subjects: 125
Study 37055459 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning architecture utilizing mobile sensing data and social networks for emotion prediction
Number of subjects: 0
Study 37055459 — intervention group
Group type: EXPERIMENTAL
Intervention: Social network integration in affect prediction
Number of subjects: 0
Study 37055566 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt substitute (62.5% NaCl and 25% KCl)
Number of subjects: 1612
Study 37055566 — intervention group
Group type: COMPARATOR
Intervention: Usual salt
Number of subjects: 1612
Study 37055566 — intervention group
Group type: COMPARATOR
Intervention: Restricted salt supply
Number of subjects: 1612
Study 37055640 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating tumour DNA (ctDNA) detection and profiling after curative intent therapy
Number of subjects: 0
Study 37055702 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-Q Blocker
Number of subjects: 150
Study 37055702 — intervention group
Group type: EXPERIMENTAL
Intervention: AuraGain
Number of subjects: 150
Study 37055702 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 150
Study 37055702 — intervention group
Group type: COMPARATOR
Intervention: All three devices
Number of subjects: 150
Study 37055724 — intervention group
Group type: EXPERIMENTAL
Intervention: Gugging Swallowing Screen (GUSS)-ICU
Number of subjects: 45
Study 37055730 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening questionnaire for early identification of risk for excessive GWG
Number of subjects: 1790
Study 37055818 — intervention group
Group type: EXPERIMENTAL
Intervention: Inversion strength test
Number of subjects: 20
Study 37055818 — intervention group
Group type: EXPERIMENTAL
Intervention: Eversion strength test
Number of subjects: 20
Study 37055818 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Leg Stance (SLS) test
Number of subjects: 20
Study 37055818 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Leg Hop for Distance (SLHD)
Number of subjects: 20
Study 37055818 — intervention group
Group type: EXPERIMENTAL
Intervention: Side Hop test
Number of subjects: 20
Study 37055818 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb Symmetry Index (LSI)
Number of subjects: 20
Study 37055818 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity of the test battery
Number of subjects: 20
Study 37055910 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan synthesis inhibitor
Number of subjects: 0
Study 37055910 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care approaches (including ACE inhibitors, ARBs, SGLT2 inhibitors, finerenone, GLP-1 receptor agonists)
Number of subjects: 0
Study 37056360 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive statin therapy
Number of subjects: 54
Study 37056363 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial pulse stimulation (TPS)
Number of subjects: 30
Study 37056363 — intervention group
Group type: COMPARATOR
Intervention: Sham TPS
Number of subjects: 30
Study 37056765 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy of 24 Gy/3 fractions/3-10 days plus liposomal irinotecan (80mg/m) followed by camrelizumab and anti-angiogenic treatment
Number of subjects: 60
Study 37057191 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Number of subjects: 40
Study 37057191 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 40
Study 37057191 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (HC)
Number of subjects: 40
Study 37057191 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab and Fingolimod
Number of subjects: 40
Study 37057394 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TG2 antibodies
Number of subjects: 0
Study 37057394 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 37057827 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Number of subjects: 1706
Study 37057827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1706
Study 37057905 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional anesthesia
Number of subjects: 8304
Study 37058047 — intervention group
Group type: COMPARATOR
Intervention: Brushing, dental floss and tongue scraper
Number of subjects: 52
Study 37058047 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing, dental floss and aPDT applied to the dorsum and middle third of the tongue
Number of subjects: 52
Study 37058047 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing, dental floss and probiotics
Number of subjects: 52
Study 37058047 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing, dental floss, aPDT and probiotics
Number of subjects: 52
Study 37058173 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab-chemotherapy
Number of subjects: 328
Study 37058173 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 328
Study 37058234 — intervention group
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T with abiraterone (STAMP trial)
Number of subjects: 0
Study 37058234 — intervention group
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T with enzalutamide (STRIDE trial)
Number of subjects: 0
Study 37058234 — intervention group
Group type: COMPARATOR
Intervention: Sequential administration of sipuleucel-T and ARTAs
Number of subjects: 0
Study 37058234 — intervention group
Group type: COMPARATOR
Intervention: Concurrent administration of sipuleucel-T and ARTAs
Number of subjects: 0
Study 37058234 — intervention group
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Number of subjects: 0
Study 37058302 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart System of Disease Management (SSDM) group
Number of subjects: 2197
Study 37058302 — intervention group
Group type: COMPARATOR
Intervention: Conventional care control group
Number of subjects: 2197
Study 37058346 — intervention group
Group type: EXPERIMENTAL
Intervention: Vet Flexiquit
Number of subjects: 49
Study 37058346 — intervention group
Group type: COMPARATOR
Intervention: SmokefreeVET
Number of subjects: 49
Study 37058414 — intervention group
Group type: EXPERIMENTAL
Intervention: QST setup with manual tests performed by a human tester
Number of subjects: 179
Study 37058414 — intervention group
Group type: EXPERIMENTAL
Intervention: QST setup with automated tests performed by a robot and orally guided by a human tester
Number of subjects: 179
Study 37058414 — intervention group
Group type: COMPARATOR
Intervention: QST setup with automated tests performed solely by a robot without social interaction
Number of subjects: 179
Study 37058426 — intervention group
Group type: EXPERIMENTAL
Intervention: quit for a bit
Number of subjects: 98
Study 37058426 — intervention group
Group type: COMPARATOR
Intervention: quit for good
Number of subjects: 98
Study 37058475 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-8 blood MRD measurement
Number of subjects: 0
Study 37058475 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-22 blood MRD measurement
Number of subjects: 0
Study 37058479 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination (2 doses)
Number of subjects: 64
Study 37058479 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies
Number of subjects: 64
Study 37058479 — intervention group
Group type: EXPERIMENTAL
Intervention: Omicron variant infection
Number of subjects: 64
Study 37058600 — intervention group
Group type: COMPARATOR
Intervention: PUFA (polyunsaturated fatty acids)
Number of subjects: 2374
Study 37058687 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus Pembrolizumab
Number of subjects: 0
Study 37058687 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37058726 — intervention group
Group type: EXPERIMENTAL
Intervention: Any opioid administration
Number of subjects: 680
Study 37058726 — intervention group
Group type: COMPARATOR
Intervention: Lowest opioid dose group
Number of subjects: 680
Study 37058726 — intervention group
Group type: COMPARATOR
Intervention: Third opioid dose group
Number of subjects: 680
Study 37058788 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobocertinib
Number of subjects: 114
Study 37058788 — intervention group
Group type: COMPARATOR
Intervention: Standard treatments
Number of subjects: 114
Study 37059239 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched/fenestrated endovascular aortic repair
Number of subjects: 1681
Study 37059261 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind Guide (mobile mindfulness app)
Number of subjects: 16
Study 37059327 — intervention group
Group type: EXPERIMENTAL
Intervention: S201086/GLPG1972 75 mg
Number of subjects: 932
Study 37059327 — intervention group
Group type: EXPERIMENTAL
Intervention: S201086/GLPG1972 150 mg
Number of subjects: 932
Study 37059327 — intervention group
Group type: EXPERIMENTAL
Intervention: S201086/GLPG1972 300 mg
Number of subjects: 932
Study 37059327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 932
Study 37059391 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation (SC) intervention
Number of subjects: 0
Study 37059391 — intervention group
Group type: COMPARATOR
Intervention: No intervention (usual care)
Number of subjects: 0
Study 37059395 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-biofortified potato meals
Number of subjects: 28
Study 37059395 — intervention group
Group type: COMPARATOR
Intervention: Nonbiofortified potato meals
Number of subjects: 28
Study 37059507 — intervention group
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab 7 mg/kg
Number of subjects: 200
Study 37059507 — intervention group
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab 10 mg/kg
Number of subjects: 200
Study 37059507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 37059508 — intervention group
Group type: EXPERIMENTAL
Intervention: Zilucoplan 0.3 mg/kg once daily by self-injection for 12 weeks
Number of subjects: 174
Study 37059508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 37059508 — intervention group
Group type: EXPERIMENTAL
Intervention: Zilucoplan
Number of subjects: 174
Study 37059696 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 350
Study 37059696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 37059702 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 2524
Study 37059702 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 4 mg/day
Number of subjects: 2524
Study 37059702 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 8 mg/day
Number of subjects: 2524
Study 37059702 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 12 mg/day
Number of subjects: 2524
Study 37059834 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib
Number of subjects: 282
Study 37060015 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened patients with PGVs (n=124)
Number of subjects: 6660
Study 37060015 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened patients without PGVs (n=776)
Number of subjects: 6660
Study 37060015 — intervention group
Group type: COMPARATOR
Intervention: Non-screened patients
Number of subjects: 6660
Study 37060015 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-negative breast cancer (TNBC) cases
Number of subjects: 6660
Study 37060015 — intervention group
Group type: EXPERIMENTAL
Intervention: ER+/HER2- cases
Number of subjects: 6660
Study 37060023 — intervention group
Group type: EXPERIMENTAL
Intervention: mPATH™-CRC program with a 'high touch' implementation strategy
Number of subjects: 0
Study 37060023 — intervention group
Group type: COMPARATOR
Intervention: mPATH™-CRC program with a 'low touch' implementation strategy
Number of subjects: 0
Study 37060023 — intervention group
Group type: EXPERIMENTAL
Intervention: mPATH™-CRC program (post-implementation cohort)
Number of subjects: 0
Study 37060023 — intervention group
Group type: COMPARATOR
Intervention: Pre-implementation cohort
Number of subjects: 0
Study 37060024 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors (ACEIs)
Number of subjects: 100
Study 37060024 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin-receptor blockers (ARBs)
Number of subjects: 100
Study 37060040 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic assisted distal radius cancellous chips graft reconstruction
Number of subjects: 88
Study 37060040 — intervention group
Group type: COMPARATOR
Intervention: Open iliac crest cancellous graft reconstruction
Number of subjects: 88
Study 37060049 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate (HR) monitoring
Number of subjects: 38
Study 37060049 — intervention group
Group type: EXPERIMENTAL
Intervention: HR-informed changes in potentially painful care procedures
Number of subjects: 38
Study 37060049 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication through HR for 6 weeks
Number of subjects: 38
Study 37060049 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-intervention HR measurement
Number of subjects: 38
Study 37060049 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in procedures for identified painful situations
Number of subjects: 38
Study 37060053 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic digital health obesity treatment intervention
Number of subjects: 18
Study 37060055 — intervention group
Group type: EXPERIMENTAL
Intervention: AGuIX nanoparticles (50, 75, and 100 mg/kg) added to standard concomitant radio-chemotherapy (temozolomide and radiotherapy)
Number of subjects: 66
Study 37060055 — intervention group
Group type: EXPERIMENTAL
Intervention: AGuIX nanoparticles with radiochemotherapy
Number of subjects: 66
Study 37060176 — intervention group
Group type: EXPERIMENTAL
Intervention: OBP-301 (oncolytic adenovirus)
Number of subjects: 20
Study 37060236 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed Starting Dose (FSD) of niraparib, 300 mg once daily
Number of subjects: 733
Study 37060236 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized Starting Dose (ISD) of niraparib, 200 mg once daily for patients with baseline body weight < 77 kg or baseline platelet count < 150,000/µL; 300 mg once daily for all other patients
Number of subjects: 733
Study 37060236 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized Starting Dose (ISD) of niraparib
Number of subjects: 733
Study 37060236 — intervention group
Group type: COMPARATOR
Intervention: Fixed Starting Dose (FSD) of niraparib
Number of subjects: 733
Study 37060288 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 8238
Study 37060288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8238
Study 37060420 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) therapy - three sessions each week for 12 weeks
Number of subjects: 32
Study 37060420 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study 37060420 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) therapy
Number of subjects: 32
Study 37060431 — intervention group
Group type: EXPERIMENTAL
Intervention: PRL3-zumab
Number of subjects: 27
Study 37060432 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix in combination with abiraterone
Number of subjects: 25
Study 37060432 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix in combination with apalutamide
Number of subjects: 25
Study 37060448 — intervention group
Group type: EXPERIMENTAL
Intervention: Subventricular zone distance (SVD) measurement from tumor edge (definition 1)
Number of subjects: 187